Fresenius-licensed Endexo Smart Polymer Gets FDA Breakthrough Status to Prevent Clots

nterface Biologics Inc. (IBI) from Canada has developed Endexo as a way to help make dialyzer membranes and bloodlines more biocompatible—and less likely to clot. The technology, for which Fresenius holds an exclusive world-wide license, will reduce the need for heparin and other blood thinners.

Read the full article » | Posted 11/16/2019

Related Articles